Dr. Saad on Recent Updates in Active Surveillance in Prostate Cancer

Fred Saad, MD, professor and chairman of Urology, director of Genitourinary Oncology, the University of Montreal Hospital Centers, discusses recent updates in active surveillance for patients with prostate cancer.

Saad reflected on the presentations given at the 2017 Genitourinary Cancers Symposium regarding active surveillance, stating that this is an exciting time for first-line treatment in prostate cancer.

Data was presented suggesting that active surveillance should be the preferred first-line option for low-risk patients with prostate cancer.

Freddie Hamdy, MD, FRCSEd, presented a 10-year study of low-risk patients with prostate cancer who were screened and randomized to either radiation therapy, surgery, or active surveillance. There was 1% cancer-specific mortality rates across all arms.

Saad believes these recent results have solidified the credibility of active surveillance as a first-line treatment.